Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Mol Genet Metab ; 125(1-2): 174-180, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-30049651

RESUMEN

OBJECTIVE: To investigate the utility of serum pyridoxal 5'-phosphate (PLP), pyridoxal (PL), and 4-pyridoxic acid (PA) as a diagnostic marker of hypophosphatasia (HPP) and an indicator of the effect of, and patient compliance with, enzyme replacement therapy (ERT), we measured PLP, PL, and PA concentrations in serum samples from HPP patients with and without ERT. METHODS: Blood samples were collected from HPP patients and serum was frozen as soon as possible (mostly within one hour). PLP, PL, and PA concentrations were analyzed using high-performance liquid chromatography with fluorescence detection after pre-column derivatization by semicarbazide. We investigated which metabolites are associated with clinical phenotypes and how these metabolites change with ERT. RESULTS: Serum samples from 20 HPP patients were analyzed. The PLP-to-PL ratio and PLP concentration were elevated in all HPP patients. They correlated negatively with serum alkaline phosphatase (ALP) activity and showed higher values in more severe phenotypes (perinatal severe and infantile HPP) compared with other phenotypes. PL concentration was reduced only in perinatal severe HPP. ERT reduced the PLP-to-PL ratio to mildly reduced or low-normal levels and the PLP concentration was reduced to normal or mildly elevated levels. Urine phosphoethanolamine (PEA) concentration did not return to normal levels with ERT in most patients. CONCLUSIONS: The serum PLP-to-PL ratio is a better indicator of the effect of ERT for HPP than serum PLP and urine PEA concentrations, and a PLP-to-PL ratio of <4.0 is a good indicator of the effect of, and patient compliance with, ERT.


Asunto(s)
Fosfatasa Alcalina/genética , Terapia de Reemplazo Enzimático , Hipofosfatasia/tratamiento farmacológico , Inmunoglobulina G/genética , Fosfato de Piridoxal/sangre , Proteínas Recombinantes de Fusión/genética , Adolescente , Adulto , Fosfatasa Alcalina/sangre , Fosfatasa Alcalina/uso terapéutico , Niño , Preescolar , Cromatografía Líquida de Alta Presión , Etanolaminas/orina , Femenino , Humanos , Hipofosfatasia/sangre , Hipofosfatasia/patología , Hipofosfatasia/orina , Inmunoglobulina G/uso terapéutico , Lactante , Recién Nacido , Masculino , Piridoxal/sangre , Ácido Piridóxico/sangre , Proteínas Recombinantes de Fusión/uso terapéutico , Vitamina B 6/metabolismo , Adulto Joven
2.
J Hum Genet ; 62(4): 473-480, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27928163

RESUMEN

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder caused by survival motor neuron gene mutations. Variant forms of SMA accompanied by additional clinical presentations have been classified as atypical SMA and are thought to be caused by variants in as yet unidentified causative genes. Here, we presented the clinical findings of two siblings with an SMA variant followed by progressive cerebral atrophy, and the results of whole-exome sequencing analyses of the family quartet that was performed to identify potential causative variants. We identified two candidate homozygous missense variants, R942Q in the tubulin-folding cofactor D (TBCD) gene and H250Q in the bromo-adjacent homology domain and coiled-coil containing 1 (BAHCC1) gene, located on chromosome 17q25.3 with an interval of 1.4 Mbp. The in silico analysis of both variants suggested that TBCD rather than BAHCC1 was likely the pathogenic gene (TBCD sensitivity, 0.68; specificity, 0.97; BAHCC1 sensitivity, 1.00; specificity, 0.00). Thus, our results show that TBCD is a likely novel candidate gene for atypical SMA with progressive cerebral atrophy. TBCD is predicted to have important functions on tubulin integrity in motor neurons as well as in the central nervous system.


Asunto(s)
Encefalopatías/genética , Proteínas Asociadas a Microtúbulos/genética , Proteínas/genética , Atrofias Musculares Espinales de la Infancia/genética , Encefalopatías/fisiopatología , Niño , Femenino , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Homocigoto , Humanos , Neuronas Motoras/patología , Mutación Missense , Linaje , Atrofias Musculares Espinales de la Infancia/fisiopatología
4.
Neurosci Lett ; 614: 83-8, 2016 Feb 12.
Artículo en Inglés | MEDLINE | ID: mdl-26773865

RESUMEN

Recent evidence suggests that neural pathways from the hindbrain to the hypothalamus are important for informing the hypothalamus of the body's condition with regard to energy metabolism. Here we examined energy metabolism in rats with transections of the midbrain that severed the neural pathway from the hindbrain to the hypothalamus, and then investigated the levels of various molecules associated with control of energy metabolism in these rats. Food intake and body weight were higher in the midbrain-transected rats than in sham-operated rats. In addition, the midbrain-transected rats showed insulin resistance and hyperleptinemia. Furthermore, the hypothalamic mRNA levels of anorectic proopiomelanocortin and cocaine- and amphetamine-related transcript were significantly lower in midbrain-transected rats than in sham-operated rats. Our findings elucidate the mechanisms of food intake and energy balance from the perspective of multifactorial regulatory systems that underlie functions such as neurohormonal integration.


Asunto(s)
Metabolismo Energético , Hipotálamo/fisiología , Rombencéfalo/fisiología , Animales , Peso Corporal , Ingestión de Alimentos , Prueba de Tolerancia a la Glucosa , Homeostasis , Resistencia a la Insulina , Leptina/sangre , Masculino , Vías Nerviosas , Proopiomelanocortina/metabolismo , ARN Mensajero/metabolismo , Ratas Wistar , Receptores de Leptina/genética , Receptores de Leptina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA